Drug analysis: MPC-150-IM

  • ID: 4462142
  • Drug Pipelines
  • 16 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

MPC-150-IM (rexlemestrocel-L; Mesoblast) consists of highly purified, immunoselected mesenchymal precursor cells (MPCs). These cells release a range of molecules that stimulate both blood vessel growth and regeneration of heart muscle, while also reducing scar formation and harmful inflammatory responses within the damaged tissues. These rare cells are isolated from tissues around the donor’s blood vessels and then expanded in large numbers before being administered to patients.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
MPC-150-IM: Chronic heart failure (CHF)

List of Figures
Figure 21: Drug assessment summary of Farxiga for chronic heart failure
Figure 22: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: MPC-150-IM drug profile
Table 2: MPC-150-IM’s late-phase trials in chronic heart failure
Table 3: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll